Skip to main content
. Author manuscript; available in PMC: 2023 Oct 5.
Published in final edited form as: Nicotine Tob Res. 2020 Oct 8;22(10):1805–1815. doi: 10.1093/ntr/ntaa031

Table 3.

Comparisons of Revised Statements With AssignedTCA Statements (Listed inTable 1) for New Information, Self-Reported Learning, andThinking About Risks

Comparison Revised statement tested New informationb
Self-reported learningc
Thinking about risksd
Revised: % describing as new information TCA: % describing as new information OR (95% CI) Revised: mean (SD) TCA: mean (SD) Regression coefficient (95% Cl) Revised: % think about risk TCA: % think about risk OR (95% Cl)

1 Mouth and throat cancer 12.9 12.2 1.07 (0.54 to 2.15) 2.51 (2.09) 2.39 (2.08) 0.13 (−0.39 to 0.65) 68.0 68.9 0.96 (0.59 to 1.58)
2 Head and neck cancer 64.2 12.2 13.26 (7.20 to 24.4)a 3.92 (1.77) 2.39 (2.08) 1.52 (1.05 to 1.99)a 68.9 68.9 1.00 (0.61 to 1.64)
3 Bladder cancer 78.9 12.2 28.15 (14.74 to 53.72)a 4.19 (1.86) 2.39 (2.08) 1.81 (1.33 to 2.28)a 70.8 68.9 1.10 (0.66 to 1.81)
4 Premature birth 17.6 8.8 2.28 (1.09 to 4.75)a 2.94 (2.24) 2.43 (2.17) 0.52 (−0.01 to 1.04) 64.9 70.9 0.76 (0.46 to 1.24)
5 Stunt fetal growth 19.0 8.8 2.49 (1.21 to 5.13)a 3.17(2.22) 2.43 (2.17) 0.75 (0.21 to 1.28)a 68.0 70.9 0.87 (0.53 to 1.44)
6 Low birth weight 19.0 8.8 2.47 (1.21 to 5.03)a 2.93 (2.17) 2.43 (2.17) 0.52 (0.00 to 1.03) 68.0 70.9 0.87 (0.52 to 1.44)
7 Respiratory illness in children 31.8 23.0 1.56 (0.93 to 2.63) 3.30 (1.95) 2.56 (2.15) 0.73 (0.25 to 1.21)a 74.3 68.9 1.31 (0.79 to 2.17)
8 Clogged arteries 32.0 16.2 2.50 (1.41 to 4.43)a 3.36(2.03) 2.70 (1.96) 0.66 (0.19 to 1.13)a 64.6 66.9 0.90 (0.56 to 1.47)
9 COPDe 36.7 41.9 0.80 (0.50 to 1.29) 3.26(2.03) 2.86 (1.99) 0.41 (−0.07 to 0.88) 71.4 56.8 1.94 (1.19 to 3.17)a
10 COPDf 29.3 16.2 2.14 (1.22 to 3.77)a 3.38 (2.00) 2.33 (2.07) 1.05 (0.56 to 1.53)a 76.9 61.5 2.13 (1.27 to 3.56)a
11 Emphysema and bronchitis 22.4 16.2 1.50 (0.83 to 2.72) 3.19(2.22) 2.33 (2.07) 0.86 (0.35 to 1.38)a 78.2 61.5 2.29 (1.36 to 3.84)a
12 Erectile dysfunction 69.4 8.8 24.43 (12.26 to 48.66)a 3.85 (1.87) 2.43 (2.17) 1.42 (0.93 to 1.90)a 55.1 70.9 0.50 (0.30 to 0.81)a
13 Amputation 66.2 16.2 10.79 (6.10 to 19.08)a 4.23 (1.78) 2.70 (1.96) 1.53 (1.09 to 1.97)a 77.7 66.9 1.75 (1.04 to 2.96)
14 Diabetes 75.5 16.2 16.01 (8.97 to 28.57)a 3.90 (1.92) 2.33 (2.07) 1.56 (1.09 to 2.03)a 56.5 61.5 0.81 (0.51 to 1.30)
15 Macular degeneration 75.5 8.8 36.90 (17.66 to 77.07)a 4.38 (1.72) 2.25 (2.17) 2.12 (1.64 to 2.60)a 71.4 55.4 2.01 (1.24 to 3.26)a
16 Cataracts 79.7 8.8 42.61 (20.73 to 87.55)a 4.28 (1.81) 2.43 (2.17) 1.85 (1.38 to 2.33)a 64.2 70.9 0.73 (0.45 to 1.20)

Regressions control for age group. Cl = confidence interval; COPD = chronic obstructive pulmonary disease; OR = odds ratio; TCA = Tobacco Control Act.

a

“Significant after adjustment for multiple comparisons.

b

Participants responded “no” or “not sure” (instead of “yes”) to the question, “Before today, had you heard about the specific smoking-related health effect described in the warning statement?”

c

Scale from 1 = “Not at all” to 7 = “Very much.”

d

“Not at all” or “A little” coded as 1 and “Somewhat” or “A lot” coded as 0.

e

Compared with fatal lung disease in nonsmokers.

f

Compared with fatal lung disease in smokers.